Viridian Therapeutics

Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Viridian Therapeutics reports strong progress in 2022 with promising trials

Viridian Therapeutics made significant strides in 2022 with positive data on VRDN-001 and plans for Phase 3 trials.
Financially, the company remains strong with $424.6 million in cash, despite increased R&D expenses.
The company's expansion into rare diseases, leadership transition, and strategic clinical site targeting showcase growth potential.
Challenges include dosing frequency impact on efficacy and operational hurdles in patient enrollment and market competition.

Viridian Therapeutics reports strong Q1 performance and strategic advancements

Viridian Therapeutics demonstrated strong performance in clinical trials and financial stability, supported by key hires and strategic partnerships, while facing challenges in investor communication and market access strategies.
The company's focus on innovation in drug delivery methods and pipeline expansion presents opportunities for growth and competitive differentiation in the biopharmaceutical industry.
Overall, Viridian's proactive approach to advancing therapeutic programs and addressing investor concerns positions the company well for future success and potential market impact.

Viridian Therapeutics excels in pipeline progress and financial stability

Viridian Therapeutics showcased strong pipeline progress and financial stability in Q1 2024, with confidence in their transformative therapies.
While facing challenges in regulatory processes and market competition, the company is poised for growth through upcoming program milestones.
Opportunities lie in expanding their therapeutic portfolio, demonstrating product efficacy, and navigating regulatory pathways effectively.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Horizon Pharma

Viridian unveiled promising results Monday for its Horizon-rivaling thyroid eye disease treatment — and the biotech stocks diverged. The post New Contender Viridian Takes Aim At Horizon's Eye Drug, And Rockets appeared first on Investor's Business Daily.

New Contender Viridian Takes Aim At Horizon's Eye Drug, And Rockets

- Positive initial clinical data from ongoing Phase 1/2 Trial evaluating VRDN-001 in patients   with Thyroid Eye Disease (TED) -

Viridian Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Updates

- Significant and rapid improvement in both signs and symptoms of TED at week 6 after two infusions of 10mg/kg VRDN-001 -

Viridian Announces Positive Initial Clinical Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)

WALTHAM, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced it will report its financial results from the second quarter ended June 30, 2022, before the financial markets open on Monday, August 15, 2022.

Viridian Therapeutics to Report Second Quarter 2022 Financial Results and Host Conference Call on August 15, 2022

Los Angeles, California--(Newsfile Corp. - June 24, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Viridian Therapeutics, Inc. ("Viridian" or "the Company") (NASDAQ: VRDN) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.If you are a shareholder who suffered a loss, click here to...

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Viridian Therapeutics, Inc. with Losses to Contact the Firm

WALTHAM, Mass., June 23, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced the appointment of Carrie Melvin as Chief Operating Officer, a newly created position at the company.

Viridian Therapeutics Appoints Carrie Melvin as Chief Operating Officer

WALTHAM, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced that Jonathan Violin, Ph.D., President and Chief Executive Officer of Viridian, will participate in two fireside chats at the Jefferies Healthcare Conference being held in New York on June 8 -10, 2022 and the JMP Securities Life Sciences Conference in New York on June 15 - 16, 2022.

Viridian Therapeutics to Participate in June Investor Conferences

Viridian Therapeutics, Inc. (NASDAQ:VRDN ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants John Jordan - VP, Investor Relations and Corporate Communications Jonathan Violin - CEO, President & Director Kristian Humer - CFO, Chief Business Officer, Principal Financial Officer & Principal Accounting Officer Conference Call Participants Christopher Howerton - Jefferies Thomas Smith - SVB Leerink Laura Chico - Wedbush Securities Rami Katkhuda - LifeSci Capital Jason Butler - JMP Securities Operator Welcome to the Viridian Therapeutics First Quarter 2022 Conference Call. [Operator Instructions].

Viridian Therapeutics, Inc. (VRDN) CEO Jonathan Violin on Q1 2022 Results - Earnings Call Transcript

Viridian Therapeutics, Inc. (VRDN) delivered earnings and revenue surprises of -6.52% and 66.77%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Lags Revenue Estimates

-- Phase 1/2 clinical trial for VRDN-001 currently recruiting Thyroid Eye Disease (TED) patients at sites in the U.S. and Canada; top line proof of concept data expected in the third quarter of 2022 -- -- Interim results for VRDN-001 in healthy volunteers show saturation of IGF-1 response at doses as low as 3 mg/kg, supporting potential efficacy of lower doses in TED --

Viridian Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Updates

WALTHAM, Mass., May 03, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced it will report its financial results from the first quarter ended March 31, 2022, after the financial markets close on Thursday, May 12, 2022.

Viridian Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call on May 12, 2022

WALTHAM, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced that Jonathan Violin, Ph.D., President and Chief Executive Officer will participate in the 21st Annual Needham Virtual Healthcare Conference on Thursday, April 14, 2022, which includes a presentation beginning at 4:30 p.m. ET.

Viridian Therapeutics to Participate in The 21st Annual Needham Virtual Healthcare Conference on April 14

WALTHAM, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced that the Company has entered into a debt financing agreement with Hercules Capital, Inc. (NYSE: HTGC) for up to $75 million.

Viridian Therapeutics Secures Flexible Credit Facility for Up to $75 Million From Hercules Capital

- VRDN-002 incorporates clinically validated half-life extension technology to support development as a low volume subcutaneous injection that could broaden settings of care -

Viridian Therapeutics Doses First Subject in First-in-Human Clinical Trial Evaluating VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease

WALTHAM, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced that Jonathan Violin, Ph.D., President and Chief Executive Officer of Viridian, will participate in a fireside chat at the 32nd Annual Oppenheimer Healthcare Conference on March 15, 2022.

Viridian Therapeutics to Participate in 32nd Annual Oppenheimer Healthcare Conference on March 15

Viridian Therapeutics' (VRDN) CEO Jonathan Violin on Q4 2021 Results - Earnings Call Transcript

-- Ongoing Phase 1/2 clinical trial for VRDN-001, an IGF-1R antibody for the treatment of Thyroid Eye Disease, is on track to report top line proof of concept data in the second quarter of 2022 -- -- VRDN-002, a distinct IGF-1R antibody incorporating validated half-life extension technology, expected to deliver top line Phase 1 clinical data in mid-2022 --

Viridian Therapeutics Reports Fourth Quarter And Full Year 2021 Financial Results And Provides Corporate Updates

WALTHAM, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced it will report its financial results from the fourth quarter and full year ended December 31, 2021, after the financial markets close on Thursday, March 10, 2022.

Viridian Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Host Investor Conference Call on March 10, 2022

WALTHAM, Mass., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced that Jonathan Violin, Ph.D., President and Chief Executive Officer will participate in a Fireside Chat at the SVB Leerink 11th Annual Global Healthcare Conference on February 18 at 2:20pm ET.

Viridian Therapeutics to Participate in the SVB Leerink 2022 Global Healthcare Conference on February 18

The FDA has signed off Viridian Therapeutics Inc's VRDN investigational new drug (IND) application of VRDN-002.  [ALERT] Nic Chahine shares his Bear Market Beating options trading strategy.

Viridian Therapeutics To Test Next-Gen IGF-1R Antibody In Thyroid Eye Disease

- VRDN-002 incorporates clinically validated half-life extension technology to support development as a low volume subcutaneous injection - - Company expects to report top line VRDN-002 Phase 1 clinical data in mid-2022 -

Viridian Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Clinical Development of VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease

- VRDN-002 is a novel anti-IGF-1R monoclonal antibody for thyroid eye disease and incorporates half-life extension technology designed to improve dosing and administration -                   - Company expects to report top line VRDN-002 phase 1 clinical data in mid-2022 -

Viridian Therapeutics Submits Investigational New Drug Application for VRDN-002 to the U.S. Food and Drug Administration

- VRDN-001 targets and blocks IGF-1R, the only mechanism of action proven to deliver efficacy in TED - - Trial is on track to deliver top line proof of concept clinical data in 2Q 2022 -

Viridian Therapeutics Announces First Subject Dosed in Phase 1/2 Clinical Trial of VRDN-001 for Thyroid Eye Disease (TED)

WALTHAM, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN) (the “Company” or “Viridian”), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced the U.S. Food and Drug Administration (“FDA”) clearance of its Investigational New Drug (“IND”) application for VRDN-001, which the Company is developing for the treatment of thyroid eye disease (TED).

Viridian Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for VRDN-001, an IGF-1R Antibody for the Treatment of Thyroid Eye Disease (TED)

Viridian Therapeutics, Inc. (VRDN) delivered earnings and revenue surprises of -5.04% and -79.20%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

News for Viridian Therapeutics Stock (VRDN)